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ABSTRACT Cysteine-rich secretory proteins (CRISPs) are widely distributed, and notably occur in themammalian reproductive
tract and in the salivary glands of venomous reptiles.Most CRISPs can inhibit ion channels, such as the cyclic nucleotide-gated ion
channel, potassium channel, and calcium channel. Natrin is a CRISP that has been puriﬁed from snake venom. Its targets include
the calcium-activated potassium channel, the voltage-gated potassium channel, and the calcium release channel/ryanodine
receptor (RyR). Immunoprecipitation experiments showed that natrin binds speciﬁcally to type 1RyR (RyR1) from skeletalmuscle.
Natrin was found to inhibit both the binding of ryanodine to RyR1, and the calcium-channel activity of RyR1. Cryo-electron
microscopy and single-particle image reconstruction analysis revealed that natrin binds to the clamp domains of RyR1. Docking of
the crystal structure of natrin into our cryo-electron microscopy density map of the RyR1 1 natrin complex suggests that natrin
inhibits RyR1 by stabilizing a domain-domain interaction, and that the cysteine-rich domain of natrin is crucial for binding. These
ﬁndings help reveal how natrin toxin inhibits the RyR calcium release channel, and they allow us to posit a generalizedmechanism
that governs the interaction between CRISPs and ion channels.
INTRODUCTION
Cysteine-rich secretory proteins (CRISPs) are single-chain
polypeptides that are characterized by the presence of 16
strictly conserved cysteine residues. Ten of these 16 cysteine
residues are clustered in the carboxyl-terminal region. The
CRISPs are widely distributed, and notably occur in the mam-
malian reproductive tract and in the salivary glands of ven-
omous reptiles.TheCRISPs are categorized into four subclasses,
according to sequencehomologyand tissue speciﬁcity.CRISP-1
was ﬁrst identiﬁed in mammalian epididymis, where it asso-
ciates with the sperm surface during epididymal maturation
and mediates sperm-egg fusion, and it is also known as acidic
epididymal glycoprotein (1,2). CRISP-2, also known as tes-
tis-speciﬁc protein-1 (Tpx-1), was found in testes and sper-
matozoa, and is thought to mediate the interaction between
spermatogenic cells and Sertoli cells (3,4). CRISP-3 was
detected in various cell types, including salivary gland, pan-
creas, prostate, and B-cells. A large number of CRISP-3 fam-
ily members are widely distributed in reptile venoms (5,6).
CRISP-4 proteins are only expressed in the epididymis, from
which they are secreted into the epididymal lumen and are
able to interact with sperm (7).
Ryanodine receptors (RyRs) are the major calcium-release
channels in striated muscle (8). They are highly enriched in
both cardiac and skeletal muscles, or more precisely, in sar-
coplasmic reticulum (SR) membrane. The SR is the major
storage site of cellular calcium. Ryanodine receptors play a
central role in excitation-contraction coupling, a process
in which neuron-induced depolarization of the plasma
membrane causes RyR molecules to release Ca21 from the
SR. The resulting increase in cytoplasmic [Ca21] activates
myoﬁlaments so as to generate muscle contraction. To date,
two CRISPs were shown to affect RyR channel functions.
Helothermine, a well-known CRISP-3 protein that was iso-
lated from the Mexican beaded lizard, can block a variety of
ion channels, including voltage-gated Ca21 channels, volt-
age-gated K1 channels, and RyRs (9–11). Helothermine in-
hibits both skeletal-muscle RyR1 and cardiac-muscle RyR2
(9). The carboxyl-terminal cysteine-rich domain (CRD) of
Tpx-1was demonstrated to inhibit RyR2, although it activates
RyR1 (12).
In addition to helothermine, many CRISP-3 proteins were
identiﬁed in venoms from a range of snakes, and were shown
to inhibit speciﬁc K1 or Ca21 ion channel activities (13–16).
Recently, the structures were determined and the functions
were explored for several CRISP-3 proteins, i.e., natrin
(17,18), stecrisp (19), and triﬂin (20). Natrin is a 221-amino-
acid toxin protein (molecular mass 25 kDa) puriﬁed from the
venom of the snake Naja naja atra. Targets of this toxin in-
clude the calcium-activated potassium channel BKCa (17) and
the voltage-gated potassium channel Kv1.3 (18). Here, we
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show that natrin binds speciﬁcally to the skeletal-muscle
RyR1, and inhibits RyR1 calcium-channel activity. To gain
insights into the structural basis of channel inhibition by
natrin, we determined the binding site of natrin in the three-
dimensional structureofRyR1, using cryo-electronmicroscopy
(cryo-EM) and single-particle image processing. Docking of
the x-ray crystal structure of natrin into the cryo-EM density
map of the RyR1 1 natrin complex indicated that the CRD
and linker domain of natrin is essential for binding, and that
the natrin molecule binds across two structural domains of
RyR1 that are important for channel regulation.
MATERIALS AND METHODS
Puriﬁcation of natrin
Natrin was puriﬁed from snake Naja naja atra, according to the published
procedure (18).
Preparation of skeletal SR vesicles
Skeletal SR vesicles were prepared from New Zealand White rabbit skeletal
muscle according to the published method, with modiﬁcations (21). Brieﬂy,
skeletal muscle was homogenized in 5 volumes (v/w) of homogenization
buffer (0.3 M sucrose, 10 mM Na-HEPES, pH 7.0, 0.5 mM EDTA, 0.2 mM
phenylmethylsulphonyl ﬂuoride, and 1:1000 diluted protease inhibitory
cocktail), and centrifuged at 11,5003 g for 20min. The supernatant was then
centrifuged at 110,0003 g for 1 h. The pellet from the last centrifugation was
collected and re-suspended in buffer (0.3 M sucrose, 10 mMNa-HEPES, pH
7.0, 0.2 mM phenylmethylsulphonyl ﬂuoride, and 1:1000 diluted protease
inhibitor cocktail), aliquoted, quick-frozen in liquid nitrogen, and stored at
80C. The protein concentration was determined by bicinchoninic-acid assay.
Puriﬁcation of RyR1
The RyR1 was puriﬁed from 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) solubilized skeletal SR, as previously described
(22,23).
Co-immunoprecipitation of natrin and RyR1
Skeletal SR (1 mg/mL) and natrin (50 mg/mL) were incubated in incubation
buffer (25 mM NaCl, 20 mM Na-HEPES, pH 7.0) without Ca21, or con-
taining 107 M Ca21, 105 M Ca21, and 103 M Ca21, respectively, for 2 h
at 4C, and then solubilized by CHAPS/soybean phospholipid, with a
CHAPS/soybean phospholipids/protein weight ratio of 13:6.5:1. After in-
cubation on ice for 30 min, samples were centrifuged at 110,0003 g for 30
min at 4C. The supernatants were collected and divided into two aliquots.
One microliter of monoclonal anti-RyR1 antibody 34C (Sigma-Aldrich, St.
Louis, MO) and 5 mL anti-natrin serum (rabbit serum raised against natrin
protein) were added to each aliquot. After incubation on ice for another 2 h,
20 mL Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology, Santa
Cruz, CA) were added, and the samples were incubated overnight at 4C. The
beads were collected by centrifugation, and washed with incubation buffer.
Proteins were resolved by electrophoresis in 3-15% linear gradient sodium
dodecyl sulfate polyacrylamide gel electrophoresis gels, transferred to
polyvinylidene diﬂuoride transfer membrane, and detected by peroxidase-
coupled antibodies.
[3H]-ryanodine binding assay
Skeletal SR vesicles (250 mg/mL) or puriﬁed RyR1 (25 mg/mL) were in-
cubated with 2 nM [3H]ryanodine in 0.2 M KCl, 20 mMNa-HEPES, pH 7.0,
and 10 mM Ca21, in a ﬁnal volume of 100 mL, containing various concen-
trations of natrin and ryanodine (for a Lineweaver-Burk plot). After incu-
bation overnight at 24C, the binding reaction was quenched by rapid
ﬁltration through Whatman (Florham Park, NJ) GF/B glass ﬁber ﬁlters
presoaked with 1% polyethyleneimine. The ﬁlters were then rinsed twice
with 10 mL of ice-cold washing buffer containing 0.2MKCl and 20mMNa-
HEPES, pH 7.0. The ﬁlters were air-dried and placed into 20-mL scintillation
vials (Kimble, Vineland, NJ), and soaked in 5 mL scintillation solution (2.5 g
(2,5-diphenyloxazole) and 150 mg (1,4-bis(5-phenyloxazol-2-yl) benzene)
in 500 mL dimethyl benzene). The ﬁlters were counted after incubation over-
night. Nonspeciﬁc binding wasmeasured in the presence of a 1000-fold excess
of unlabeled ryanodine. The experiments were repeated at least twice, and on
two different skeletal SR vesicles and on puriﬁed RyR1 preparations.
Calcium efﬂux from skeletal SR vesicles
Calcium efﬂux measurements were carried out according to the published
procedure (24). Brieﬂy, skeletal SR vesicles (100 mg/mL) were added to a
2-mL solution containing 100 mM KH2PO4, pH 7.0, 4 mM MgCl2, 1 mM
Na2ATP, and 0.5 mM antipyrylazo III. The temperature was maintained at
25C. Extravesicular [Ca21] was monitored at 710 nm, using a Hitachi
U2010 spectrophotometer (Hitachi, Tokyo, Japan). Vesicles were loaded
with Ca21 by the addition of four aliquots of CaCl2, each initially increasing
the extravesicular Ca21 concentration by 7.5 mM over the previous pre-
ceding concentration. Sufﬁcient time (2–5 min) was allowed between one
addition of Ca21 and the next, so that the uptake reduced the Ca21 con-
centration to baseline level. Then 200 nM thapsigargin in H2O, 200 nM
thapsigargin in buffer (30 mM KCl, 25 mM Na-HEPES, pH 7.0), or 200 nM
thapsigargin with 0.5 mM natrin in buffer (30 mM KCl, 25 mM Na-HEPES,
pH 7.0) were added to suppress Ca21-ATPase activity and to allow extra-
vesicular [Ca21] to increase. The calcium efﬂux was measured for another
5 min, and ruthenium red (5 mM) was added to conﬁrm that Ca21 release
was occurring through RyR1 channels. Finally, the Ca21 ionophore A23187
(3 mg/mL) was added, to release all Ca21 remaining in the vesicles.
Cryo-EM and image processing
Cryo-electron microscopy was carried out as described previously (25).
Images were processed using the SPIDER/WEB software package (26).
Three-dimensional reconstructions of RyR1 and the RyR11 natrin complex
were computed according to the projection matching method (25). The ﬁnal
three-dimensional reconstructions of the RyR1 control and the RyR1 1
natrin complex were computed from 16,519 and 7959 particles, respectively.
The resolution for both reconstructions was 21 A˚, according to the Fourier
shell correlation criterion, with a cutoff of 0.5 (27). An x-ray crystal structure
of natrin (Protein Data Bank code 2GIZ) was docked into the cryo-EM
density of the three-dimensional difference map manually, using the molecular
graphics programsO (http://xray.bmc.uu.se/;alwyn/index.html) and Chimera
(http://www.cgl.ucsf.edu/chimera/). Various possible ﬁtting orientations were
evaluated by the correlation coefﬁcient using the SPIDER program, and the
best-ﬁtting orientation was chosen using the highest correlation coefﬁcient (28).
RESULTS
Previous studies showed that natrin toxin can block the cal-
cium-activated potassium channel BKCa (17) and the volt-
age-gated potassium channel Kv1.3 (18). In this study, we
address the following questions: Does natrin bind speciﬁcally
to RyR1? If so, what is the functional effect of natrin-binding
on the RyR1 calcium release channel? Where is the natrin-
binding site in the three-dimensional structure of RyR1? Can
the structural information obtained from the binding-site de-
termination be used to explain any functional effect of natrin
on RyR1?
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Natrin binds speciﬁcally to RyR1
The speciﬁc binding between RyR1 and natrin toxin was
tested in co-immunoprecipitation experiments. As shown in
Fig. 1 A, RyR1s were precipitated by rabbit serum raised
against natrin, and in Fig. 1 B, natrin proteins were precipi-
tated by anti-RyR1 antibody. These co-immunoprecipitation
experiments clearly demonstrated that natrin toxin binds
speciﬁcally to RyR1.
Natrin toxin reduces [3H]ryanodine binding
to RyR1
After the co-immunoprecipitation experiments, we examined
the functional effects of natrin on the RyR1 calcium- release
channel, by carrying out [3H]ryanodine binding assays.
Ryanodine binding reﬂects the open probability of the calcium
channel, because ryanodine is known to bind speciﬁcally to
RyR in its open conformation (29). As shown in Fig. 2, A and
D, natrin toxin produced a strong inhibition of [3H]ryanodine
binding, both to skeletal muscle SR vesicles and to puriﬁed
RyR1 molecules. The half-maximal inhibitory concentration
of natrin was found to be 3.1mMfor SR vesicles, and 1.03mM
for puriﬁed RyR1.
Next, we performed equilibrium saturation assays of
[3H]-ryanodine binding to skeletal SR vesicles (Fig. 2 B) and
to puriﬁed RyR1s (Fig. 2 E). Fig. 2, B and E, shows that
natrin reduced [3H]ryanodine’s capability to bind both SR
vesicles and puriﬁed RyR1s. For SR vesicles, a Lineweaver-
Burk plot (Fig. 2 C) visualized that 3 mM natrin reduced the
total binding capacity (Bmax) of [
3H]ryanodine from 9.27 to
4.21 pmol/mg, whereas the binding afﬁnity was virtually
unchanged, as revealed by the dissociation constant (Kd) that
only changed from 15.63 to 17.68 nM. For puriﬁed RyR1s,
1mMnatrin reduced the Bmax of [
3H]ryanodine from 49.75 to
18.93 pmol/mg, whereas the Kd changed slightly, from 20.25
to 23.01 nM (Fig. 2 F). These kinetic data suggest that natrin
toxin behaves as a typical noncompetitive antagonist of
RyR1: it binds to a site distinct from the ryanodine-binding
site. We think that the reduction of our Bmax is attributable to
the binding of natrin inhibiting the conformational changes of
RyR1 (see Discussion), blocking the access and reducing the
binding of ryanodine to the binding sites, because ryanodine
is known to bind speciﬁcally to RyR1 in its open confor-
mation (29). However, other explanations are also possible,
e.g., the effects of natrin toxin, just as of ruthenium red, could
involve blocking the low-afﬁnity binding site while non-
competitively altering high-afﬁnity binding (30). Additional
experiments will be necessary to understand the reduced
(apparent) Bmax.
In addition,we investigated the effects of natrin and various
RyR1 channel modulators on [3H]ryanodine binding to
skeletal SR vesicles. The modulators tested were the oxidiz-
ing and reducing reagents H2O2 and dithiothreitol (DTT), the
RyR1 channel activators ATP and caffeine, and the RyR1
channel inhibitorsMg21 and Ca21 (at mM concentrations). As
shown in Fig. 3 A, in the absence of natrin, 5 mM H2O2 in-
creased [3H]ryanodine binding to SR vesicles from 1.13 6
0.06 (mean6 SD, n¼ 2) to 3.076 0.07 pmol/mg (n¼ 2), and
2 mMDTT decreased binding to 0.236 0.007 pmol/mg (n¼
2). When SR vesicles were treated additionally with 3 mM
natrin, [3H]ryanodine binding was reduced to 0.46 6 0.01
(n¼ 2, control), 0.376 0.06 (n¼ 2, 5mMH2O2), and 0.136
0.01 pmol/mg (n¼ 2, 2mMDTT). The RyR1 activators 5mM
caffeine and 5mMATP both increased [3H]ryanodine binding
from1.136 0.06pmol/mg (n¼ 2) to 5.186 0.11 forATP (n¼
2), and from 1.13 6 0.06 pmol/mg to 1.33 6 0.03 pmol/mg
for caffeine (n ¼ 2, Fig. 3 B). When SR vesicles were treated
additionally with of 3 mM natrin, the corresponding ryanodine
binding decreased to 4.596 0.27 (n¼ 2) and 0.676 0.01 (n¼
2) pmol/mg, respectively (Fig. 3 B). Under inhibitory condi-
tions, 1 mM MgCl2 and 0.5 mM CaCl2 decreased [
3H]ryano-
dine binding to 0.116 0.02 (n ¼ 2) and 0.396 0.01 (n ¼ 2)
pmol/mg (without natrin), respectively, and the addition of
3mMnatrin decreased binding further to 0.076 0.005 (n¼ 2)
or 0.156 0.006 (n¼ 2) pmol/mg (Fig. 3 C). In summary, the
[3H]ryanodine binding data demonstrate that natrin toxin in-
hibits [3H]ryanodine binding for RyR1 channels in skeletal SR
in both its activated and inactivated states, as well as under a
variety of redox modiﬁcations.
Natrin toxin blocks RyR1 calcium-release
channel activity
To examine further the effects of that natrin on RyR1 channel
activity, we visualized Ca21 efﬂux events by RyR1 from
native SR vesicles in real time. Extravesicular [Ca21] was
monitored by a Ca21 indicator, antipyrylazo III (24). Skeletal
SR vesicles were partially loaded with Ca21 by four se-
quential additions of CaCl2, each initially increasing the ex-
travesicular [Ca21] by ;7.5 mM from the preceding level
FIGURE 1 Co-immunoprecipitation of natrin and RyR1. (A) RyR1 pre-
cipitation by anti-natrin antiserum. The RyR1 bands are indicated. Lane 1,
skeletal SR; lane 2, anti-natrin anti-serum; lane 3, natrin; lane 4, buffer
(control); lanes 5–8, SR incubated with natrin at 0 M Ca21, 107 M Ca21,
105 M Ca21, and 103 M Ca21, respectively. (B) Natrin precipitation by
anti-RyR1 antibody. Natrin bands are indicated. Lane 1, natrin; lanes 2–5, SR
incubated with natrin at 0 MCa21, 107 M Ca21, 105 M Ca21, and 103 M
Ca21, respectively; lane 6, control buffer.
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(Fig. 4 A). After suppression of Ca21-ATPase activity by the
addition of 200 nM thapsigargin, the rates of Ca21 efﬂuxwere
recorded. Changes in ﬂuorescence intensity, corresponding to
calcium efﬂux events, were recorded for 10 min after the
addition of thapsigargin, and while extravesicular [Ca21] was
still increasing, we added ruthenium red (5 mM) to stop the
Ca21 efﬂux, conﬁrming that RyR1 channels were mediating
this calcium efﬂux event. Finally, the Ca21 ionophore
A23187 (3 mg/mL) was added to release all Ca21 remaining
in the SR vesicles.
As shown in Fig. 4 B, in the absence of natrin toxin, the
maximal rate of calcium efﬂux was 52.82 6 4.62 nmol/mg/
min (200 nM thapsigargin in H2O; mean 6 SE, n ¼ 12) and
59.28 6 4.01 nmol/mg/min (200 nM thapsigargin in buffer;
n ¼ 8). When 0.5 mM natrin was added with thapsigargin,
the maximal release rate was reduced to 31.69 6 4.38 nmol/
mg/min (200 nM thapsigargin1 0.5 mM natrin; n¼ 11, p,
0.05). These data demonstrate that natrin inhibits calcium
release from SR through the RyR1 channel.
Two-dimensional image-averaging
and classiﬁcation
The puriﬁed natrin toxinwas incubatedwithRyR1 to promote
complex formation. The samples were applied to carbon-
coated electron microscopy grids, which were then rapidly
frozen in liquid ethane. Both the RyR1 1 natrin complexes
and the control RyR1 (without added natrin toxin) were im-
aged by cryo-EM. Fig. 5 A shows a typical electron micro-
graph in which the individual RyR1 1 natrin complexes are
visible.
Ryanodine receptor-1 is a homo-tetramer that consists of
four identical subunits and possesses fourfold symmetry in its
three-dimensional structure (31). By selecting particles with
their fourfold-symmetry axes that oriented perpendicular to
the carbon support ﬁlm, we computed two-dimensional av-
erages (Fig. 5 B). This view represents a projection of the
three-dimensional structure of RyR as seen from the cyto-
plasmic side (i.e., three-dimensional view in Fig. 5B). Overall
FIGURE 2 Natrin toxin reduces [3H]ryanodine
binding to RyR1. Concentration dependence for
blockage of [3H]ryanodine binding to skeletal SR
vesicles (A) and to puriﬁed RyR1 (D). The SR
vesicles (0.25 mg/mL) or puriﬁed RyR1 (25 mg/
mL) were incubated (see Materials and Methods)
with various concentrations of natrin (0–10 mM) in
binding buffer containing 10 mM [Ca21] and 2 nM
[3H]ryanodine. We also preformed equilibrium sat-
uration assays of [3H]ryanodine binding to skeletal
SR vesicles (B and C) and to puriﬁed RyR1 (E and
F). Experiments were performed in binding buffer
containing 10 mM [Ca21], 2 nM [3H]ryanodine, and
various concentrations of unlabeled ryanodine
(1–64 nM). (B) Saturation curve of [3H]ryanodine
binding to skeletal SR vesicles in the absence or
presence of 3 mM natrin. (C) Data-ﬁtting according
to Lineweaver-Burk equation. (E) Saturation curve
of [3H]ryanodine binding to puriﬁed RyR1 in
absence or presence of 1 mM natrin. (F) Data-
ﬁtting.
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the two-dimensional average for RyR1 1 natrin agreed
closelywith that for the RyR1 control, apart from the presence
of small regions of additional density. To identify the subtle
differences between RyR11 natrin and the RyR1 control, we
created a difference map through subtraction of the image of
the RyR1 control average from that of RyR1 1 natrin. The
brightest areas shown in the difference map in Fig. 5 B rep-
resent the proteinmass present in theRyR11 natrin complex,
but absent in the RyR1 control (one corner is highlighted by a
white circle). The location sites of increased mass density
were located in regions that correspond to the ‘‘clamp’’ (i.e.,
assemblages of domains that form the corners of the square-
shaped cytoplasmic part of the receptor) in the three-dimen-
sional structure ofRyR1 (green dotswere used to highlight the
relative position in two-dimensional averages and in the three-
dimensional view). The four maximum differences almost
certainly correspond to the additional masses attributable to
the binding of four natrin molecules to one RyR1 tetramer,
an interpretation conﬁrmed by a more precise mapping of
natrin-binding sites within the three-dimensional structure
(see below).
Before computing the three-dimensional reconstruction of
the RyR1 1 natrin complex, we had to address a problem of
heterogeneity of the data set, caused by partial occupancy
of the four natrin-binding sites on one RyR1 homo-tetramer.
Because the binding afﬁnity between natrin and puriﬁed
RyR1 is;1mM,we estimated that, under the conditions used
for cryo-EM, ;90% of the natrin-binding sites on RyR1
should be occupied. However, this estimate is for optimal
binding conditions, and the actual binding on electron mi-
croscopy grids is likely to be lower. For RyR1, the case is even
more complicated, because each RyR1 tetramer has four
natrin-binding sites. Besides the RyR1 molecules showing full
occupancy, bound with four natrin molecules (Fig. 5 C, right),
there are ﬁve other categories of RyR1 molecules that show
less than the full complement of four bound natrin molecules
(i.e., with 0, 1, 2, or 3 natrin molecules; furthermore, there are
two categories of RyR1 1 natrin complexes with two natrin
FIGURE 3 Effects of RyR1 channel modulators on natrin inhibition of
[3H]ryanodine binding to skeletal SR vesicles. Equilibrium [3H]ryanodine
binding experiments, in different redox states (A), or in presence of channel
activators (B) or channel inhibitors (C), were performed both with and
without 3 mM natrin. Experimental conditions were the same as in Fig. 2.
Data are presented as mean 6 SD.
FIGURE 4 Natrin toxin blocks RyR1 calcium efﬂux from skeletal SR
vesicles. (A) Extravesicular [Ca21] was monitored by the Ca21 indicator,
antipyrylazo III. (Blue) 200 nM thapsigargin in H2O; (green) 200 nM
thapsigargin in buffer (30 mM KCl, 25 mM Na-HEPES, pH 7.0); (red)
200 nM thapsigargin 1 0.5 mM natrin in buffer (30 mM KCl, 25 mM
Na-HEPES, pH 7.0). (B) Averaged maximal rates of calcium efﬂux with or
without natrin. Data are presented as mean 6 SE.
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molecules bound, as depicted in Fig. 5C,middle). To estimate
the actual percentages of RyR1with the various complements
of bound natrin molecules, we performed a two-dimensional
classiﬁcation analysis. Top images of RyR1 1 natrin com-
plexes (N ¼ 1142) were subjected to a multireference super-
vised classiﬁcation (32). As shown in Fig. 5C,;48.9% of the
particles had four natrinmolecules bound,whereas 51.1%had
fewer. This classiﬁcation scheme allowed us to eliminate
most of the incompletely occupied RyR1 particles in the
subsequent image-processing. We only used particles with
natrin-binding sites fully occupied to compute the ﬁnal three-
dimensional reconstruction of the RyR1 1 natrin complex.
Determination of natrin-binding locations in
three-dimensional structure of RyR1
Fig. 6, A and B, shows surface representations of three-
dimensional reconstructions of the control RyR1 andRyR11
natrin complex, in three views. The ﬁnal resolution was esti-
mated to be 21 A˚ by Fourier shell correlation, with a cutoff of
0.5 (27). The reconstructions show the distinctive mushroom
shape of RyR, consisting of a large cytoplasmic assembly
with at least 11 domains, and the smaller transmembrane
domain assembly (31,33). As expected from the two-dimen-
sional data, the two reconstructions are highly comparable,
but an obvious difference appears on the top surface of do-
mains 5 and 6, as shown in the side views in Fig. 6, A and B
(red circles). We generated a three-dimensional difference
map by subtracting the volume of the control RyR1 from the
volume of the RyR1 1 natrin complex. The main positive
difference regions are superimposed on the three-dimensional
reconstruction of control RyR1 (Fig. 6 C, orange). This dif-
ferencemap clearly indicates that there is one bound natrin per
RyR1 subunit, located at the top surface of domains 5 and 6.
The three-dimensional locations of the natrin-binding site are
also consistent with the two-dimensional difference map.
Docking the crystal structure of natrin into the
cryo-EM density map of the RyR1 1
natrin complex
The atomic structure of natrin toxin was solved by x-ray
crystallography (18). It consists of three domains: a patho-
genesis-related protein of the group 1 (PR-1)-like domain
(residues 6–160), a short linker (residues 161–182), and the
CRD (residues 183–221). A docking of the atomic structure
of natrin was performed interactively by ﬁtting the atomic
coordinates (Protein Data Bank code 2GIZ) into the cryo-EM
surface envelope of the RyR1 1 natrin map. Because the
three-dimensional structure of the RyR1 1 natrin complex
was reconstructed from RyR1 with natrin fully bound parti-
cles, the crystal structure of natrin ﬁtted quite well into the
cryo-EM density map that assigned to the natrin molecule,
the cross-correlation coefﬁcient value between the difference
map and the ﬁtted atomic coordinates is 0.76, as determined
by the SPIDER program (28). Other docking orientations,
e.g., a 180 rotation around the vertical axis (switching the
CRD and linker domain) or a 180 rotation around the hori-
zontal axis (switching the linker and PR-1 domain), gave lower
cross-correlation coefﬁcient values. Additional studies, e.g.,
improving the resolution of the RyR1 1 natrin complex and
ﬂexible docking, are needed to reﬁne our docking model
FIGURE 5 Cryo-electron microscopy
and two-dimensional analysis. (A) Por-
tion of cryo-EM micrograph of RyR11
natrin complexes, showing individual
complexes embedded in a thin layer of
vitreous ice. The tetrameric structure of
RyR1 is well-preserved. Several indi-
vidual particles are marked with white
circles. Scale bar, 500 A˚. (B) Two-
dimensional averages of top views of
RyR1 control and RyR11 natrin. Two-
dimensional top view of RyR1 1 natrin
was averaged from 245 particle images,
and two-dimensional top view of RyR1
control was averaged from 266 particle
images. The difference map was ob-
tained by subtracting the RyR1 control
average from the RyR1 1 natrin aver-
age. Top view represents the projection
of RyR1 as seen from the cytoplasmic
side, as depicted in a reference image
of the three-dimensional structure. The
largest differences shown in the differ-
ence map, corresponding to additional
masses contributed by the binding of natrin molecules, are seen as density-maxima bright white areas, and are encircled. The corresponding location of major
difference in the difference map is also highlighted by green dots. The width of each frame is 544 A˚. (C). Partial occupancy of natrin-binding sites on RyR1
particles. Green dots represent binding sites occupied with natrin molecules (see text for details).
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further. Fig. 7 illustrates the ﬁtting of natrin in a viewwhere the
cytoplasmic-facing side is tilted from the fourfold symmetry
axis. Only small portions of three loops (residues 30–31, 107–
110, and 135–137), and of two a-helices (residues 11–13, not
visible in this view, and 98–99) from the PR-1 domain of
natrin protrude beyond the electron microscopy density. De-
tails of docking results are shown in Supplementary Material,
Movie S1. Our docking model clearly indicates that the linker
domain and the CRD of natrin directly interact with domains
5 and 6 of RyR1, respectively (Fig. 7 B), whereas the PR-1
domain points away from RyR1, and thus does not appear to
participate in binding.
FIGURE 6 Three-dimensional surface representations of RyR1 control and RyR1 1 natrin complex, and three-dimensional difference map. Three-
dimensional reconstruction of RyR1 control is shown in yellow (A), and RyR11 natrin complex is shown in orange (B). (C) Difference map (RyR11 natrin
minus RyR1, orange) is superimposed on three-dimensional reconstruction of RyR1 control (yellow). Three-dimensional reconstructions are shown in three
views: (left) top view from cytoplasmic surface, which in situ would face the transverse tubule; (middle) side view; (right) bottom view showing surface that
would face the SR lumen. Numerals 1–11 on the cytoplasmic assembly indicate distinguishable domains, according to our earlier nomenclature (31,33).
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DISCUSSION
Natrin blocks the RyR1 calcium-release channel
by stabilizing a domain-domain interaction
within RyR1
Domains 5 and 6 in RyR1, with which the natrin toxin directly
interacts, contain the two mutation hotspots that we previously
mapped (34,35). Over 100 mutations in RyR1 were identiﬁed
in families with malignant hyperthermia and central-core dis-
ease, and these mutations are largely clustered in three regions
of the ;5,000-amino-acid sequence of RyR1: the amino-ter-
minal region (amino-acid residues 35–614), central region
(amino-acid residues 1728–2728), and carboxyl-terminal re-
gion (amino-acid residues 3348–4973) (36). The twomutation
hotspots that lie in the cytoplasmic region, the amino-terminal
region, and the central region are well-separated in the primary
sequence (.1100 amino acids). According to a hypothesis
proposed by Ikemoto and Yamamoto (37), the two mutation
hotspots occur in structural domains that physically interact in
the three-dimensional structure, and changes in the strength of
their interaction affect channel gating. In that hypothesis, the
amino-terminal domain and central domain interact so as to
serve as a regulatory switch for channel-gating activity; a tight
‘‘zipping’’ of the interacting domains stabilizes the channel in
the closed state. A mutation in either domain weakens the
domain-domain interaction, thus increasing the tendency to-
ward ‘‘unzipping.’’ Such an unzipping causes activation and
leakiness of the Ca21 release channel. In support of their
hypothesis, the authors found that addition of the synthetic
peptides DP4 (corresponding to the Leu2442-Pro2477 region in
RyR1’s central mutation domain) or DP1 (corresponding to
Leu590-Cys609 in RyR1’s N-terminal mutation domain) en-
hanced [3H]ryanodine binding and inducedCa21 release from
the SR (38,39). The synthetic peptide DP4 also induced
contraction in skinned muscle ﬁbers at an inhibitory Mg21
concentration (40), and increased the frequency of Ca21
sparks in saponin-permeabilized ﬁbers because of an in-
creased open probability of the channels (41).
Previous studies pertaining to interdomain interactions
relied mainly on indirect biochemical assays to detect con-
formational changes in RyR isoforms, either RyR1 or RyR2
(38,39), and little information describing local or global
changes in RyR1’s three-dimensional architecture has been
reported. We used three-dimensional cryo-EM to test the
domain-switch hypothesis, i.e., to determine the three-di-
mensional localization of the two mutation hotspots. We
previously mapped one central mutation hotspot (Ser2367) in
the three-dimensional structure of RyR2 by green ﬂuorescent
protein (GFP) labeling (34). Another site in the amino-ter-
minal mutation hotspot (Ser437) was located by the same
method (35). The GFP inserted in the amino-terminal region
sequence (Ser437) was mapped to a region near domains 5 and
9, whereas the GFP in the central region (Ser2367) mapped to
the bridge between domains 5 and 6 (labeled N and C in Fig.
7 C). Although those results were obtained for the structure of
FIGURE 7 Docking of x-ray crystal structure of natrin into cryo-EM
density map of RyR1 1 natrin complex. Atomic coordinates of natrin
molecule (Protein Data Bank code 2GIZ) were manually ﬁtted into our cryo-
EM density map of RyR11 natrin complex, using the program O. (A) Tilted
view of RyR11 natrin complex with one natrin molecule docked in natrin-
binding site of one subunit in RyR1 homo-tetramer. (B) A zoom view of
clamp region from A, showing that natrin binds to domains 5 and 6 of RyR1.
Domain rendering of natrin molecule: PR-1 domain (amino-acid residues
1–160, blue), linker (residues 161–182, green), and CRD (residues 183-221,
red). Numbers indicate residues that protrude slightly out of the density map
envelope. (C) Detailed view of clamp-shaped structure, showing relative
positions of previously mapped amino-terminal (N) and central (C) mutation
hotspots.
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RyR2, they can be extrapolated to RyR1 because of the high
degree of sequence identity (42,43) and structural similarity of
the two isoforms (31,44). Fig. 7 C shows that the two GFP-
mapped locations are on opposite sides of domain 5 in the
clamp region of the RyR cytoplasmic assembly, a spatial re-
lationship consistent with the interdomain zipping-unzipping
hypothesis of Ikemoto and Yamamoto (37).
Our structural information, together with the domain-
switch hypothesis, leads us to propose a molecular mecha-
nism for natrin’s inhibition of the RyR1 calcium-release
channel. As illustrated in Fig. 7C, the CRD of natrin interacts
with the central mutation domain, and the linker interacts
with the N-terminal domain. It is likely that the binding of
natrin to RyR1 strengthens the interaction between the two
domains, thereby minimizing domain-switch unzipping and
stabilizing the closed state of the RyR1 channel. As revealed
in three-dimensional reconstruction, the binding of natrin
caused domains 5 and 6 to approach closer to one another.
These movements also appear prominently in the two-di-
mensional difference map as two dark (negative) density
areas (corresponding to the reduced mass attributable to the
movement of domains) next to the bright white (positive)
density maxima (attributable mainly to the additional mass of
natrin and secondarily to domain movements).
Our ﬁndings are pertinent to the development of novel
therapeutics for muscular dystrophies. Dantrolene is a drug
that suppresses RyR1 Ca21 release from SR in skeletal
muscle, and is used as a therapeutic agent in individuals
susceptible to malignant hyperthermia (45). In addition,
JTV519 is a 1,4-benzothiazepine derivative, found to im-
prove contractility and to prevent the development of calcium
leak through the inhibition of the mutant cardiac RyR2 and
skeletal RyR1 (46). Both drugs stabilize RyR by restoring the
domain-domain interaction that is disordered by disease-
causing mutations (46,47). Moreover, fatigue of skeletal
muscles is directly linked to the channel leakage of RyR1,
and an RyR1 stabilizer can block the leakage, reduce muscle
damage, and boost stamina in mice (48).
CRD is the binding domain that directly interacts
with various ion channels
Our docking model reveals that the CRD and the linker are
the major parts of the natrin molecule that directly interact
with RyR1. In an earlier study, the CRD of Tpx-1, a CRISP-2
subclass protein, was demonstrated to inhibit RyR2, whereas
it activated RyR1 (12). Previous studies also attributed the
interaction between other ion channels and CRISPs to the
CRD. Stecrisp is another snake-venom toxin that belongs to
the CRISP-3 family, and the CRD of stecrisp has structural
features similar to those of two ion channel blockers, Bgk and
Shk (19). Isolated from the sea anemone, Bgk and Shk are
37-residue and 35-residue peptides that function as voltage-
sensitive K1 channel blockers (49,50). Natrin and stecrisp
show a high degree of sequence identity, and can also block
the BKCa channel (17) and the Kv1.3 channel (18). Natrin
also shows high sequence homology with other two CRISPs,
pseudechetoxin and pseudecin. These are two ion channel
blockers that target the cyclic nucleotide-gated ion channel
(19). For both of these latter CRISPs, the CRD contains the
site of interaction with the target cyclic nucleotide-gated ion
channels (51,52). Another study demonstrated that the CRD
of natrin plays a crucial role in the interaction between this
toxin and the Kv1.3 potassium channel (18). Taken together,
these ﬁndings suggest the existence of a familial mode of
interaction of the CRISPs with their various targeted ion
channels. In each case, the CRD is the domain of the CRISP
that binds to the channel, and thereby modulates its func-
tioning.
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